This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by de Simone, G. Articles by Contaldo, F. Search for Related Content PubMed PubMed Citation Articles by de Simone, G. Articles by Contaldo, F. Related Collections Clinical Studies Hypertrophy Obesity Echocardiography Cell signalling/signal transduction

(Hypertension. 2001;38:13.)
© 2001 American Heart Association, Inc.

Brief Review

Link of Nonhemodynamic Factors to Hemodynamic Determinants of Left Ventricular Hypertrophy

Giovanni de Simone; Fabrizio Pasanisi; Franco Contaldo

From the Department of Clinical and Experimental Medicine, Federico II University Hospital School of Medicine, Naples, Italy.

Correspondence to Giovanni de Simone, MD, Echocardiography Laboratory, Department of Clinical and Experimental Medicine, Federico II University Hospital, via Sergio Pansini, 5, 80131, Naples, Italy. E-mail simogi{at}unina.it

	Abstract

Top Abstract Introduction Genotype Gender Body Size Nonhemodynamic Factors Are Also... Conclusions References

 
Abstract—— Despite current evidence suggesting that hemodynamic load is the fundamental stimulus to begin the sequence of biological events leading to the development of left ventricular hypertrophy, genotype, gender, body size, and less easily recognizable environmental factors may contribute to generate the cascade of molecular changes that eventually yield the increase in protein synthesis needed to increase left ventricular mass. However, even nonhemodynamic factors such as gender and body size eventually regulate the growth of left ventricular mass by at least in part influencing loading conditions. Consideration of measurable factors, such as gender, body size, and hemodynamic load, allows evaluation of individual echocardiographic left ventricular mass as the deviation from the level that would be required to face a gender-specific hemodynamic load at a given body size. Values of left ventricular mass that are inappropriately high for individual gender, body size, and hemodynamic load are associated with a high cardiovascular risk phenotype, even independent of the presence of arterial hypertension. Thus, the condition of inappropriately high left ventricular mass may be recognized as a more advanced stage of pathological structural changes initially induced by overload, going beyond the compensatory needs. The biological process that yields inappropriate left ventricular mass is probably linked to the protracted activity over time of biological mediators of left ventricular hypertrophy, such as proto-oncogenes and other growth factors, neurohormones, and cytokines, inducing structural modifications that initially compensate imposed overload but eventually change the structure of myocardial tissue and the composition of motor units.

Key Words: hypertrophy • gender • genotype • growth factors • hemodynamics • blood pressure

	Introduction

Top Abstract Introduction Genotype Gender Body Size Nonhemodynamic Factors Are Also... Conclusions References

 
Myocardial hypertrophy is the chronic adaptation of the left ventricle (LV) to increased cardiac load. Increased wall stress and strain provide a stimulus for signaling to cause mRNA transcription to increase muscular proteins. This prompt nuclear reaction is finalized to protect the myocardium from excessive wall tension by minimizing oxygen consumption and simultaneously producing sufficient strength to provide the body tissue with the required nutriment by maintaining or even increasing cardiac output. Thus, hemodynamic factors are at the basis of molecular changes that eventually yield the cascade of reactions needed to achieve those compensatory goals.^1–4

Studies and experiments performed on the pathways that lead to the increased protein synthesis that ultimately causes LV hypertrophy have provided the assumption that LV hypertrophy might also occur in the absence of clear-cut, recognizable changes in cardiac loading conditions.^5–9 Although this possibility appears to be true under experimental conditions in which direct exposures of cells to growth factors are investigated, independent of the hemodynamic factors known to be the stimuli for production of those substances, the applicability of those experiments to the intact circulation in humans remains to be proved. However, the difficulty of attributing most of the cross-sectional variability of LV mass in humans to the variability of blood pressure^10,11 has lead to the opinion that the entire process of the development of hypertensive LV hypertrophy is not necessarily associated with clearly identifiable hemodynamic alterations. Thus, the question of whether LV hypertrophy in human hypertension is a pure consequence of hemodynamic overload had been raised at the beginning of echocardiographic studies on cardiac adaptation to arterial hypertension.¹²

Despite the current evidence suggesting that hemodynamic load is the basic initial stimulus to begin the sequence of biological events that lead to the development of LV hypertrophy, there are at least 3 recognizable, potent stimuli for LV growth other than those generally considered as direct hemodynamic factors: genotype, gender, and body size. These factors do not appear to be immediately related to hemodynamics, although they eventually are. With these potent determinants, less easily recognizable environmental factors, especially those related to nutritional habits,^13,14 might directly or indirectly contribute to the variability of LV mass.

	Genotype

Top Abstract Introduction Genotype Gender Body Size Nonhemodynamic Factors Are Also... Conclusions References

 
The number of human cardiac myocytes is genetically determined and reaches a final amount within the first year after birth, when mitotic activity ceases.¹⁵ Genotype is therefore very likely to be the primary stimulus for the construction of the myocardial architecture on which further stimuli will determine the degree of growth of cell size (hypertrophy). This genetic effect has been shown in studies of twins. Harshfield et al¹⁶ measured LV mass in 7 sets of monozygotic and 15 sets of dizygotic twins. After adjustments for gender, blood pressure, age, and caloric expenditure, monozygotic twins showed smaller within-pair differences (7±5 g/m²) and much higher intraclass correlation (=0.90, P<0.01) than dizygotic twins (17±11 g/m², P<0.03; =0.33, P=NS), suggesting that the magnitude of LV mass was at least in part genetically determined. Recent studies in the cohort of the HyperGEN¹⁷ have confirmed that part of the variability of LV mass is in fact genetically determined.

The "normal" inherited genotype can, however, be altered by the signal transduction of mechanical stress, through the activation of protein kinase cascades of phosphorylation and the expression of immediate-early genes such as c-fos, c-myc, c-jun, and Egr-1, inducing an increase in protein synthesis, and the late response of locally produced neurohormones and genes such as ß-myosin heavy chain and skeletal -actin, altering the tissue structure.¹⁸

	Gender

Top Abstract Introduction Genotype Gender Body Size Nonhemodynamic Factors Are Also... Conclusions References

 
LV mass does not differ between boys and girls during infancy and childhood, suggesting that the initial number of cardiac myocytes is likely to be similar in males and females.^19,20 A clear-cut gender difference in LV mass becomes evident at puberty, when gender-specific hormonal influences are imposed on the original anatomic pattern established by the genetically determined number of cardiomyocytes. Gender difference in LV mass increases during adolescence and remains constant during adulthood. These gender differences are sustained by the symmetric increase in both chamber dimension and wall thickness, yielding no gender difference in relative wall thickness.

	Body Size

Top Abstract Introduction Genotype Gender Body Size Nonhemodynamic Factors Are Also... Conclusions References

 
The gender difference in LV growth evidenced during the pubertal period and then adolescence, and sustained during adulthood, however, is almost entirely due to covariance with body size.¹⁹ Despite a different rate of growth, because of the physiological decline in metabolic rate from birth to adulthood,²¹ a study performed in 341 twins²² demonstrated that genes common to LV mass and body weight significantly influence the covariability of these variables and that >90% of the correlation of LV mass and weight is indeed owing to common genes. In that study, univariate genetic analyses documented that genotype accounted for a significant proportion of the variance of LV mass in both boys and girls, even after removal of the effect of weight and sexual maturity through regression methods. These studies suggested that in the presence of "normal" cardiac loading conditions, body size is the most important bioassay of heart size, but it does not completely offset the effect of male hormones.

The impact of body size on LV mass is also a function of body composition. In the study from the Medical College of Virginia, Goble et al²⁰ analyzed 243 children, aged 7 to 11, using stepwise regression models. They found that body weight, but not ponderosity, was a strong predictor of LV mass, whereas body fat was negatively associated with LV mass. The authors suggested that lean body mass can account for much of variability in cardiac growth seen in children, whereas the influence of hemodynamic variables was limited, in that study, to normotensive children. Daniels et al²³ confirmed the speculation of Goble et al in a study in which 201 normotensive children (6 to 17 years old, 105 boys and 96 girls, 103 whites and 98 blacks) were studied using dual-energy x-ray absorptiometry to measure lean body mass and fat mass. In multiple regression analysis, lean body mass accounted for 75% of the variance of LV mass, with negligible additional contributions from fat mass and systolic blood pressure (1.5% and 0.5% of the variance, respectively). In that study, lean body mass was the strongest determinant of LV mass in both males and females in both whites and blacks. With normalization for lean body mass, the gender difference in LV mass almost completely disappears.²⁴

For these reasons, when body weight increases because of increasing fat mass, the physiological relation between body size and LV mass, mostly due to covariance with lean body mass, is lost, because the variations in body weight are mostly due to an increase in fat mass. Because most of the resting energy expenditure depends on fat-free mass, with the contribution of fat mass being negligible,²⁵ normalization of LV mass for body weight or other measures of body size that are body weight dependent (ie, body surface area) do not represent the real impact of body size when body composition is severely altered, as happens in obesity.

A surrogate of fat-free mass is body height. In mammals, height (or length) is determined by skeletal size, which is in turn related to muscle mass. Skeletal structure is therefore built for a given amount of muscle.²⁶ As a consequence, body length or height is a strong biological correlate of the "ideal" lean body mass, and in fact, a close relation between skeletal and lean body mass has been demonstrated in humans with the use of dual-energy x-ray absorptiometry.^27,28 Because of the geometric disproportion between height (a linear measure) and LV mass (a 3-dimensional variable generated by a cubic function), the relation is linear only when height is raised to an exponent close to 3, which is called "allometric signal." This exponent has been identified to be between 2.7 and 3 in different epidemiological studies.^29–31 Indexation of LV mass for height (m^2.7) can be useful when attempting to measure the impact of abnormalities of body composition on LV anatomy, such as in obesity or anorexia nervosa, although it is not necessarily better for prognostic purposes.^32,33

The mechanisms through which the metabolically active lean body mass influences the magnitude of LV mass is related to the metabolic requirements to maintain the resting energy balance,²⁵ but it is also genetically determined, although this genetic link might be more complex than suggested in available studies.²²

	Nonhemodynamic Factors Are Also Hemodynamic Stimuli

Top Abstract Introduction Genotype Gender Body Size Nonhemodynamic Factors Are Also... Conclusions References

 
In addition to affecting body build and LV weight, genotype influences cardiac loading conditions. Genetic factors that determine within-family similarities of blood pressure may be detected early in life,³⁴ but they may also be detected much later. In 289 pairs of elderly Swedish twins, the importance of genetic and environmental influences on blood pressure was evaluated using a design able to discriminate the importance of shared rearing environments and genetic effects³⁵: genetic factors were observed to play an important role in individual differences in blood pressure, but substantial influences of shared family effects were also demonstrated. In another study,³⁶ systolic and diastolic blood pressures were measured in 254 monozygotic and 260 dizygotic middle-aged male twin pairs and then remeasured twice during a follow-up. Heritability was 0.5 at each time point. Genetic variation present at middle age contributed 60% to the variability detected 9 years later, with the remaining 40% being new. Significant genetic covariations were also reported for systolic and diastolic blood pressure during cold-pressor test³⁷ in 91 monozygotic and 41 dizygotic normal twin pairs aged 34±14 years. Most recently, Snieder et al³⁸ reported a higher heritability for augmentation index (radial waveform, measured by applanation tonometry) than for blood pressure traits in 225 monozygotic and 594 dizygotic female white twin pairs aged 18 to 73 years. This study was implemented on the assumption that <50% of the variance in LV mass is accounted for by conventional factors such as age, blood pressure, and body size, but hemodynamic volume load was not considered. This is in fact the case when only the pressure component of cardiac load is considered, which is not necessarily the most important hemodynamic predictor of LV mass.¹¹

Cardiac work is indeed caused by displacement of a given volume of blood through development of a pressure able to overcome aortic impedance.³⁹ This work, sustained by a given amount of LV mass, can be represented by the product of stroke volume and mean systolic pressure and can be approximated by multiplying stroke volume by cuff brachial systolic (or mean) blood pressure. Stroke work is closely related to LV mass, as well as to body size, as was recently demonstrated⁴⁰ in a large normotensive, normal-weight population study that encompassed the entire life span (Figure). In an age-weighted regression model generated in the entire study population (n=766), gender, body size (height in m^2.7), and stroke work accounted for up to 86% of variability of LV mass, with only 14% of variance unexplained. In that study, the ability of body size to accurately predict LV weight was very high at birth and decreased progressively toward adolescence to reach a stable scatter during adulthood. Age was identified as the source of such increasing error of body size prediction (heteroscedastic distribution of residuals), and its effect was attributed, in the hypothesis of the study, to the increasing variability of loading conditions, because of the superimposition of unmeasured factors. Interestingly, although stroke work increased markedly during childhood and adolescence, body growth remained the main determinant of LV mass in this age stratum, and until puberty, male gender also had a lower impact than body size. In contrast, after puberty, during adulthood, when body size was more stabilized by the completion of physiological growth, the influence of changes in body size was minimal, whereas the variability of stroke work became the overwhelming correlate of LV mass and the effect of male gender became more important.

View larger version (39K): [in this window] [in a new window]   Interrelation among LV mass (top, y axis), stroke work (central top, x axis; right middle, y axis), and body weight (right, x axis) in 611 normotensive, normal-weight individuals (from de Simone et al40). LV mass is closely related to stroke work and body size, and stroke work is closely related to body size. The magnitude of the relations is very similar, reflecting a strict biological colinearity.

Using the unweighted regression equation from the entire study population,⁴⁰ we could determine that after consideration of the hemodynamic load, body height (as a measure of fat-free mass) accounts for 37% of the explained variance of LV mass, whereas male gender accounts for only 5% of variability. The 18% of variance of LV mass that remained statistically unexplained in the unweighted regression model could be because of either intrinsic error of measurements or, perhaps mainly, undetected (in this study) genetic influences other than those affecting cardiac workload and body size, which were estimated to be 9%.

The real limitation of these studies in relating LV mass to stroke work might be the fact that both LV mass and stroke volume are computed with the same primary echocardiographic measurements. The consequent obvious colinearity might reduce the impact of those findings, making at least part of the relation spurious, because of mathematical tautology. The obvious method to partially overcome this tautology is to measure LV mass or stroke volume with different primary measures, a procedure that has been used.¹¹ However, in symmetrically contracting hearts, this risk of tautology is possibly minimized.

With these limitations taken into account, an evaluation of gender-specific LV mass in relation to cardiac workload at a given body size theoretically allows the need to use normal distribution–based partition values for the identification of LV hypertrophy to be overcome and allows a "qualitative" estimation of the increase in LV mass. Theoretically, every value of observed LV mass that exceeds 100% of the predicted value should be considered as abnormally elevated, but the probability that this excess might have biological relevance can be graduated according to a reference normal distribution (Table).

View this table: [in this window] [in a new window]   Table 1. Percentile of Distribution LV Mass Values as Percent Deviation From That Predicted by Gender, Height (m2.7), and Stroke Work in the Normal-Weight, Normotensive Adult Reference Population

Biological Mediators for LV Hypertrophy
The pathways through which different stimuli yield increase in LV mass are most likely common and involve immediate stretch-induced expression of early proto-oncogenes and intramyocardial transcription of neurohormones (angiotensin II, aldosterone, endothelin, bradykinin, and so on).⁴¹ Neurohormones have hemodynamic activity, but being produced locally, they are also direct growth factors.^42,43 The regulation of other mediators of cell growth, including cytokines, growth hormone (GH), and insulin-like growth factor 1 (IGF-1), also plays an important role in LV remodeling by influencing myocardial growth and composition^44–48 and eventually contributing to promote the regression to a fetal program of gene expression that may represent the transition from a compensatory type of LV hypertrophy to a severe alteration of myocardial structure that leads to heart failure.^49,50 IGF-1 was recently reported to be independently associated with LV mass in the PIUMA cohort.⁵¹ In a experiment in rats, cardiac IGF-1 mRNA has been shown to be upregulated by angiotensin II, through hemodynamic and nonhemodynamic mechanisms, respectively, and was found to modulate cardiac structural changes that occur in hypertension.⁵² There also is emerging evidence of the direct effect of GH in the response of the LV to a number of physiological and pathological stimuli that increase cardiac load.^46,53–55 GH/IGF-1 pathways can also help to explain the link among obesity, increase in blood pressure, development of LV hypertrophy, and metabolic syndrome.^56–58

Overall, the results of these studies suggest that the process of hypertrophy begins immediately at the time of increase in mechanical strain and progresses to a stage at which its compensatory finality is lost but biological mechanisms are still potently activated. At this stage, myocardial growth parallels progressive alteration in tissue composition, with increase in extracellular matrix and fibroblast invasion as the most evident consequences. The information we are gaining from the characterization of functional and grossly anatomical features of inappropriate LV mass in hypertensive or normotensive individuals^59,60 suggests that the transition from a compensatory to a decompensated stage of LV hypertrophy might be even clinically recognized.

Other factors might facilitate hemodynamic signaling for the production of local neurohormonal mediators. Two factors might have particular biological relevance to many shared cardiovascular consequences of hypertension and obesity: insulin resistance and salt intake.

Insulin influences many biological pathways in addition to the glucose metabolism,⁶¹ has hemodynamic effects (vasodilatation),^62,63 and is a potent growth factor.⁶⁴ Resistance to the utilization of glucose, occurring to some extent in hypertension and obesity, does not imply that the other hormone effects are also blunted,⁶⁵ but it causes a substantial increase in insulin production in the attempt to maintain a normal rate of utilization of glucose. Both insulin resistance and the resulting hyperinsulinemic status have consequences on the cardiovascular system,⁶⁶ although this effect might not be independent of other demographic and hemodynamic correlates.^67,68

An indirect mechanism through which insulin might also influence LV growth is related to its ability to increase sodium retention,⁶¹ therefore coupling another important (although not unanimously considered) stimulus for LV growth. Sodium intake has been shown to be a potent determinant of LV growth in hypertensive as well as in normotensive experimental animal models, through complex mechanisms that involve circulating volume expansion and possible activation of the tissue renin-angiotensin system.^69–71 In humans, the effect of high sodium intake is more difficult to isolate from other biological determinants of LV mass, the most important of which is obesity. The overall high caloric intake of overweight individuals tracks a high sodium intake. Studies that compare the effect of a reduction in sodium and/or caloric intake have shown that the decrease in blood pressure can be optimized by combining low sodium with low caloric intake,⁷² suggesting that the same might happen for LV mass.

	Conclusions

Top Abstract Introduction Genotype Gender Body Size Nonhemodynamic Factors Are Also... Conclusions References

 
LV growth depends on hemodynamic load influenced by genetic and environmental factors. The extend to which an individual LV reacts to hemodynamic stimuli is related to the ability to produce a cascade of events that start at the level of the cell membrane, yielding eventually increased production of growth factors. This ability is most probably under direct genetic control but also is independently related to the magnitude of body size and to the influence of gender-specific hormones, raising their activity at the time of adolescence. Because of the individual specificity of LV weight, the recognition of individual gender-specific ideal LV mass appropriate for cardiac work, at a given body size, might help discrimination of pathological from compensatory LV hypertrophy.

Received September 15, 2000; first decision October 10, 2000; accepted December 13, 2000.

	References

Top Abstract Introduction Genotype Gender Body Size Nonhemodynamic Factors Are Also... Conclusions References

 

1. Weber KT, Brilla CG. Structural basis for pathologic left ventricular hypertrophy. Clin Cardiol. 1993; 16 (suppl 2): II-10–II-4.
2. Yamazaki T, Komuro I, Kudoh S, Zou Y, Shiojima I, Mizuno T, Takano H, Hiroi Y, Ueki K, Tobe K. Mechanical stress activates protein kinase cascade of phosphorylation in neonatal rat cardiac myocytes. J Clin Invest. 1995; 96: 438–446.
3. Sadoshima J, Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol. 1997; 59: 551–571.[Medline] [Order article via Infotrieve]
4. Komuro I. Molecular mechanism of mechanical stress-induced cardiac hypertrophy. Jpn Heart J. 2000; 41: 117–129.[Medline] [Order article via Infotrieve]
5. Susic D, Nunez E, Frohlich ED, Prakash O. Angiotensin II increases left ventricular mass without affecting myosin isoform mRNAs. Hypertension. 1996; 28: 265–268.[Abstract/Free Full Text]
6. Schunkert H, Sadoshima J, Cornelius T, Kagaya Y, Weinberg EO, Izumo S, Riegger G, Lorell BH. Angiotensin II-induced growth responses in isolated adult rat hearts: evidence for load-independent induction of cardiac protein synthesis by angiotensin II. Circ Res. 1995; 76: 489–497.[Abstract/Free Full Text]
7. Paul M, Ganten D. The molecular basis of cardiovascular hypertrophy: the role of the renin-angiotensin system. J Cardiovasc Pharmacol. 1992; 19 (suppl 5): S51–S58.
8. Kaneko K, Susic D, Nunez E, Frohlich ED. ACE inhibition reduces left ventricular mass independent of pressure without affecting coronary flow and flow reserve in spontaneously hypertensive rats. Am J Med Sci. 1997; 314: 21–27.[Medline] [Order article via Infotrieve]
9. Dzau VJ. Implications of local angiotensin production in cardiovascular physiology and pharmacology. Am J Cardiol. 1987; 59: 59A–65A.[Medline] [Order article via Infotrieve]
10. Devereux RB, Savage DD, Sachs I, Laragh JH. Relation of hemodynamic load to left ventricular hypertrophy and performance in hypertension. Am J Cardiol. 1983; 51: 171–176.[Medline] [Order article via Infotrieve]
11. Ganau A, Devereux RB, Pickering TG, Roman MJ, Schnall PL, Santucci S, Spitzer MC, Laragh JH. Relation of left ventricular hemodynamic load and contractile performance to left ventricular mass in hypertension. Circulation. 1990; 81: 25–36.[Abstract/Free Full Text]
12. Frohlich ED, Tarazi RC. Is arterial pressure the sole factor responsible for hypertensive cardiac hypertrophy? Am J Cardiol. 1979; 44: 959–963.[Medline] [Order article via Infotrieve]
13. Kumanyika SK, Hebert PR, Cutler JA, Lasser VI, Sugars CP, Steffen-Batey L, Brewer AA, Cameron M, Shepek LD, Cook NR. Feasibility and efficacy of sodium reduction in the Trials of Hypertension Prevention, phase I. Trials of Hypertension Prevention Collaborative Research Group. Hypertension. 1993; 22: 502–512.[Abstract/Free Full Text]
14. Preuss HG, Gondal JA, Lieberman S. Association of macronutrients and energy intake with hypertension. J Am Coll Nutr. 1996; 15: 21–35.[Abstract]
15. Zak R. Development and proliferative capacity of cardiac muscle cells. Circ Res. 1974; 35: 17–26.
16. Harshfield GA, Grim CE, Hwang C, Savage DD, Anderson SJ. Genetic and environmental influences on echocardiographically determined left ventricular mass in black twins. Am J Hypertens. 1990; 3: 538–543.[Medline] [Order article via Infotrieve]
17. Arnett D, Devereux RB, Hong Y, Rao DC, Oberman A, Kitzman DW, Hopkins PN. Strong heritability of left ventricular mass in hypertensive African Americans and relative wall thickness in hypertensive whites: the HyperGEN Echocardiography Study. Circulation. 1998; 98 (suppl I): I-658.Abstract.
18. Yamazaki T, Komuro I, Yazaki Y. Molecular mechanism of cardiac cellular hypertrophy by mechanical stress. J Mol Cell Cardiol. 1995; 27: 133–140.[Medline] [Order article via Infotrieve]
19. de Simone G, Devereux R, Daniels S, Meyer R. Gender differences in left ventricular growth. Hypertension. 1995; 26: 979–983.[Abstract/Free Full Text]
20. Goble MM, Mosteller M, Moskowitz WB, Schieken RM. Sex differences in the determinants of left ventricular mass in childhood. The Medical College of Virginia Twin Study. Circulation. 1992; 85: 1661–1665.[Abstract/Free Full Text]
21. Schmidt-Nielsen K. Scaling: Why Is Animal Size So Important? Cambridge, UK: Cambridge University Press; 1984: 56–89.
22. Verhaaren HA, Schieken RM, Mosteller M, Hewitt JK, Eaves LJ, Nance WE. Bivariate genetic analysis of left ventricular mass and weight in pubertal twins (the Medical College of Virginia twin study). Am J Cardiol. 1991; 68: 661–668.[Medline] [Order article via Infotrieve]
23. Daniels SR, Kimball TR, Morrison JA, Khoury P, Witt S, Meyer RA. Effect of lean body mass, fat mass, blood pressure, and sexual maturation on left ventricular mass in children and adolescents: statistical, biological, and clinical significance. Circulation. 1995; 92: 3249–3254.[Abstract/Free Full Text]
24. Hammond IW, Devereux RB, Alderman MH, Laragh JH. Relation of blood pressure and body build to left ventricular mass in normotensive and hypertensive employed adults. J Am Coll Cardiol. 1988; 12: 996–1004.[Abstract]
25. Nelson KM, Weinsier RL, Long CL, Schutz Y. Prediction of resting energy expenditure from fat-free mass and fat mass. Am J Clin Nutr. 1992; 56: 848–856.[Abstract/Free Full Text]
26. Biewener AA. Locomotory stresses in the limb bones of two small mammals: the ground squirrel and chipmunk. J Exp Biol. 1983; 103: 131–154.[Abstract/Free Full Text]
27. Aloia JF, Vaswani A, Ma R, Flaster E. To what extent is bone mass determined by fat-free or fat mass? Am J Clin Nutr. 1995; 61: 1110–1114.[Abstract/Free Full Text]
28. Aloia JF, Vaswani A, Ma R, Flaster E. Comparative study of body composition by dual-energy x-ray absorptiometry. J Nucl Med. 1995; 36: 1392–1397.[Abstract/Free Full Text]
29. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, Alderman MH. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol. 1992; 20: 1251–1260.[Abstract]
30. Urbina EM, Gidding SS, Bao W, Pickoff AS, Berdusis K, Berenson GS. Effect of body size, ponderosity, and blood pressure on left ventricular growth in children and young adults in the Bogalusa Heart Study. Circulation. 1995; 91: 2400–2406.[Abstract/Free Full Text]
31. Daniels SR, Kimball TR, Morrison JA, Khoury P, Meyer RA. Indexing left ventricular mass to account for differences in body size in children and adolescents without cardiovascular disease. Am J Cardiol. 1995; 76: 699–701.[Medline] [Order article via Infotrieve]
32. Liao Y, Cooper RS, Durazo-Arvizu R, Mensah GA, Ghali JK. Prediction of mortality risk by different methods of indexation for left ventricular mass. J Am Coll Cardiol. 1997; 29: 641–647.[Abstract]
33. de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol. 1995; 25: 1056–1062.[Abstract]
34. Levine RS, Hennekens CH, Duncan RC, Robertson EG, Gourley JE, Cassady JC, Gelband H. Blood pressure in infant twins: birth to 6 months of age. Hypertension. 1980; 2 (suppl I): I-29–I-33.
35. Hong Y, de Faire U, Heller DA, McClearn GE, Pedersen N. Genetic and environmental influences on blood pressure in elderly twins. Hypertension. 1994; 24: 663–670.[Abstract/Free Full Text]
36. Colletto GM, Cardon LR, Fulker DW. A genetic and environmental time series analysis of blood pressure in male twins. Genet Epidemiol. 1993; 10: 533–538.[Medline] [Order article via Infotrieve]
37. Busjahn A, Faulhaber HD, Viken RJ, Rose RJ, Luft FC. Genetic influences on blood pressure with the cold-pressor test: a twin study. J Hypertens. 1996; 14: 1195–1199.[Medline] [Order article via Infotrieve]
38. Snieder H, Hayward CS, Perks U, Kelly RP, Kelly PJ, Spector TD. Heritability of central systolic pressure augmentation: a twin study. Hypertension. 2000; 35: 574–579.[Abstract/Free Full Text]
39. Dreslinski GR, Messerli FH, Dunn FG, Frohlich ED. Early hypertension and cardiac work. Am J Cardiol. 1982; 50: 149–151.[Medline] [Order article via Infotrieve]
40. de Simone G, Devereux RB, Kimball TR, Mureddu GF, Roman MJ, Contaldo F, Daniels SR. Interaction between body size and cardiac workload: influence on left ventricular mass during body growth and adulthood. Hypertension. 1998; 31: 1077–1082.[Abstract/Free Full Text]
41. Frohlich ED. Overview of hemodynamic and non-hemodynamic factors associated with left ventricular hypertrophy. J Mol Cell Cardiol. 1989; 21 (suppl 5): 3–10.
42. Morgan HE, Baker KM. Cardiac hypertrophy: mechanical, neural, and endocrine dependence. Circulation. 1991; 83: 13–25.[Free Full Text]
43. Weber KT, Sun Y, Guarda E. Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension. 1994; 23: 869–877.[Abstract/Free Full Text]
44. Booz GW, Baker KM. Molecular signalling mechanisms controlling growth and function of cardiac fibroblasts. Cardiovasc Res. 1995; 30: 537–543.[Medline] [Order article via Infotrieve]
45. Ruwhof C, van der LA. Mechanical stress-induced cardiac hypertrophy: mechanisms and signal transduction pathways. Cardiovasc Res. 2000; 47: 23–37.[Abstract/Free Full Text]
46. Tanaka N, Ryoke T, Hongo M, Mao L, Rockman HA, Clark RG, Ross J, Jr. Effects of growth hormone and IGF-I on cardiac hypertrophy and gene expression in mice. Am J Physiol. 1998; 275(2 pt 2): H393–H399.
47. Minniti G, Jaffrain-Rea ML, Moroni C, Baldelli R, Ferretti E, Cassone R, Gulino A, Tamburrano G. Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics. Clin Endocrinol (Oxf). 1998; 49: 101–106.[Medline] [Order article via Infotrieve]
48. Isgaard J, Tivesten A, Friberg P, Bengtsson BA. The role of the GH/IGF-I axis for cardiac function and structure. Horm Metab Res. 1999; 31: 50–54.[Medline] [Order article via Infotrieve]
49. Weber KT. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation. 1997; 96: 4065–4082.[Free Full Text]
50. Lorell BH. Transition from hypertrophy to failure. Circulation. 1997; 96: 3824–3827.
51. Verdecchia P, Reboldi G, Schillaci G, Borgioni C, Ciucci A, Telera MP, Santeusanio F, Porcellati C, Brunetti P. Circulating insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension. Circulation. 1999; 100: 1802–1807.[Abstract/Free Full Text]
52. Brink M, Chrast J, Price SR, Mitch WE, Delafontaine P. Angiotensin II stimulates gene expression of cardiac insulin-like growth factor I and its receptor through effects on blood pressure and food intake. Hypertension. 1999; 34: 1053–1059.[Abstract/Free Full Text]
53. Beshyah SA, Shahi M, Foale R, Johnston DG. Cardiovascular effects of prolonged growth hormone replacement in adults. J Intern Med. 1995; 237: 35–42.[Medline] [Order article via Infotrieve]
54. Eliakim A, Brasel JA, Mohan S, Wong WLT, Cooper DM. Increased physical activity and the growth hormone-IGF-I axis in adolescent males. Am J Physiol. 1998; 275(1 pt 2): R308–R314.
55. Segev Y, Landau D, Rasch R, Flyvbjerg A, Phillip M. Growth hormone receptor antagonism prevents early renal changes in nonobese diabetic mice. J Am Soc Nephrol. 1999; 10: 2374–2381.[Abstract/Free Full Text]
56. Grimm D, Cameron D, Griese DP, Riegger GA, Kromer EP. Differential effects of growth hormone on cardiomyocyte and extracellular matrix protein remodeling following experimental myocardial infarction. Cardiovasc Res. 1998; 40: 297–306.[Abstract/Free Full Text]
57. Kokot F, Adamczak M, Wiecek A, Cieplok J. Does leptin play a role in the pathogenesis of essential hypertension? Kidney Blood Press Res. 1999; 22: 154–160.[Medline] [Order article via Infotrieve]
58. Johannsson G, Bengtsson BA. Growth hormone and the metabolic syndrome. J Endocrinol Invest. 1999; 22 (5 suppl): 41–46.[Medline] [Order article via Infotrieve]
59. Palmieri V, de Simone G, Roman M, Shwartz J, Pickering T, Devereux R. Ambulatory blood pressure and metabolic abnormalities in hypertensive patients with inappropriately high left ventricular mass. Hypertension. 1999; 34: 1032–1040.[Abstract/Free Full Text]
60. Celentano A, Palmieri V, Di Palma Esposito N, Pietropaolo I, Crivaro M, Mureddu GF, Devereux RB, de Simone G. Inappropriate left ventricular mass in normotensive and hypertensive patients. Am J Cardiol. 2001; 87: 361–363.[Medline] [Order article via Infotrieve]
61. Ferrannini E, Galvan AQ, Gastaldelli A, Camastra S, Sironi AM, Toschi E, Baldi S, Frascerra S, Monzani F, Antonelli A, Nannipieri M, Mari A, Seghieri G, Natali A, Insulin. new roles for an ancient hormone. Eur J Clin Invest. 1999; 29: 842–852.[Medline] [Order article via Infotrieve]
62. Baron AD, Brechtel G. Insulin differentially regulates systemic and skeletal muscle vascular resistance. Am J Physiol. 1993; 265(1 pt 1): E61–E67.[Abstract/Free Full Text]
63. Lembo G, Iaccarino G, Vecchione C, Rendina V, Parrella L, Trimarco B. Insulin modulation of ß-adrenergic vasodilator pathway in human forearm. Circulation. 1996; 93: 1403–1410.[Abstract/Free Full Text]
64. Ulrich RG, Cramer CT, Adams LA, Kletzien RF. Activation and glucagon regulation of mitogen-activated protein kinases (MAPK) by insulin and epidermal growth factor in cultured rat and human hepatocytes. Cell Biochem Funct. 1998; 16: 77–85.[Medline] [Order article via Infotrieve]
65. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991; 14: 173–194.[Abstract]
66. Ferrannini E, Natali A, Capaldo B, Lehtovirta M, Jacob S, Yki-Jarvinen H. Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR). Hypertension. 1997; 30: 1144–1149.[Abstract/Free Full Text]
67. Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med. 2000; 248: 245–254.[Medline] [Order article via Infotrieve]
68. de Simone G, Devereux RB, Palmieri V, Roman MJ, Lee ET, Celentano A, Fabsitz RR, Howard BV. Association of insulin resistance with markers of preclinical cardiovascular disease: the Strong Heart Study. Circulation. 2000 (Suppl II): II-835.Abstract.
69. Frohlich ED, Chien Y, Sesoko S, Pegram BL. Relationship between dietary sodium intake, hemodynamics, and cardiac mass in SHR and WKY rats. Am J Physiol. 1993; 264(1 pt 2): R30–R34.[Abstract/Free Full Text]
70. de Simone G, Devereux RB, Camargo MJ, Wallerson DC, Laragh JH. Influence of sodium intake on in vivo left ventricular anatomy in experimental renovascular hypertension. Am J Physiol. 1993; 264(6 pt 2): H2103–H2110.[Abstract/Free Full Text]
71. de Simone G, Devereux RB, Camargo MJ, Wallerson DC, Sealey JE, Laragh JH. Reduction of development of left ventricular hypertrophy in salt-loaded Dahl salt-sensitive rats by angiotensin II receptor inhibition. Am J Hypertens. 1996; 9: 216–222.[Medline] [Order article via Infotrieve]
72. The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. Arch Intern Med. 1997; 157: 657–667.[Abstract]

This article has been cited by other articles:

				A. E. Malavazos, F. Ermetici, L. Morricone, A. Delnevo, C. Coman, B. Ambrosi, and M. M. Corsi Association of Increased Plasma Cardiotrophin-1 With Left Ventricular Mass Indexes in Normotensive Morbid Obesity Hypertension, February 1, 2008; 51(2): e8 - e8. [Full Text] [PDF]

				A L Markel, O E Redina, M A Gilinsky, G M Dymshits, E V Kalashnikova, Y. V Khvorostova, L A Fedoseeva, and G S Jacobson Neuroendocrine profiling in inherited stress-induced arterial hypertension rat strain with stress-sensitive arterial hypertension J. Endocrinol., December 1, 2007; 195(3): 439 - 450. [Abstract] [Full Text] [PDF]

				B. Lopez, J. M. Castellano, A. Gonzalez, J. Barba, and J. Diez Association of Increased Plasma Cardiotrophin-1 With Inappropriate Left Ventricular Mass in Essential Hypertension Hypertension, November 1, 2007; 50(5): 977 - 983. [Abstract] [Full Text] [PDF]

				Y. Abe, K. Ono, T. Kawamura, H. Wada, T. Kita, A. Shimatsu, and K. Hasegawa Leptin induces elongation of cardiac myocytes and causes eccentric left ventricular dilatation with compensation Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2387 - H2396. [Abstract] [Full Text] [PDF]

				L. Perego, P. Pizzocri, D. Corradi, F. Maisano, M. Paganelli, P. Fiorina, M. Barbieri, A. Morabito, G. Paolisso, F. Folli, et al. Circulating Leptin Correlates with Left Ventricular Mass in Morbid (Grade III) Obesity before and after Weight Loss Induced by Bariatric Surgery: A Potential Role for Leptin in Mediating Human Left Ventricular Hypertrophy J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4087 - 4093. [Abstract] [Full Text] [PDF]

				T. Kuznetsova, J. A. Staessen, L. Thijs, C. Kunath, A. Olszanecka, A. Ryabikov, V. Tikhonoff, K. Stolarz, G. Bianchi, E. Casiglia, et al. Left Ventricular Mass in Relation to Genetic Variation in Angiotensin II Receptors, Renin System Genes, and Sodium Excretion Circulation, October 26, 2004; 110(17): 2644 - 2650. [Abstract] [Full Text] [PDF]

				P. Andersson, E. Rydberg, and R. Willenheimer Primary hyperparathyroidism and heart disease -- a review Eur. Heart J., October 2, 2004; 25(20): 1776 - 1787. [Abstract] [Full Text] [PDF]

				F. Orio Jr., S. Palomba, L. Spinelli, T. Cascella, L. Tauchmanova, F. Zullo, G. Lombardi, and A. Colao The Cardiovascular Risk of Young Women with Polycystic Ovary Syndrome: An Observational, Analytical, Prospective Case-Control Study J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3696 - 3701. [Abstract] [Full Text] [PDF]

				H.-C. Han, K. J. Austin, P. W. Nathanielsz, S. P. Ford, M. J. Nijland, and T. R. Hansen Maternal nutrient restriction alters gene expression in the ovine fetal heart J. Physiol., July 1, 2004; 558(1): 111 - 121. [Abstract] [Full Text] [PDF]

				R. M.A. Henry, O. Kamp, P. J. Kostense, A. M.W. Spijkerman, J. M. Dekker, R. van Eijck, G. Nijpels, R. J. Heine, L. M. Bouter, and C. D.A. Stehouwer Left Ventricular Mass Increases With Deteriorating Glucose Tolerance, Especially in Women: Independence of Increased Arterial Stiffness or Decreased Flow-Mediated Dilation: The Hoorn Study Diabetes Care, February 1, 2004; 27(2): 522 - 529. [Abstract] [Full Text] [PDF]

				G. de Simone Left Ventricular Geometry and Hypotension in End-Stage Renal Disease: A Mechanical Perspective J. Am. Soc. Nephrol., October 1, 2003; 14(10): 2421 - 2427. [Abstract] [Full Text] [PDF]

				L. A. Barouch, D. E. Berkowitz, R. W. Harrison, C. P. O'Donnell, and J. M. Hare Disruption of Leptin Signaling Contributes to Cardiac Hypertrophy Independently of Body Weight in Mice Circulation, August 12, 2003; 108(6): 754 - 759. [Abstract] [Full Text] [PDF]

				G. de Simone, P. Verdecchia, S. Pede, M. Gorini, and A. P. Maggioni Prognosis of Inappropriate Left Ventricular Mass in Hypertension: The MAVI Study Hypertension, October 1, 2002; 40(4): 470 - 476. [Abstract] [Full Text] [PDF]

				C. Dekkers, F. A. Treiber, G. Kapuku, E. J.C.G. van den Oord, and H. Snieder Growth of Left Ventricular Mass in African American and European American Youth Hypertension, May 1, 2002; 39(5): 943 - 951. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited